Affordable Access

deepdyve-link
Publisher Website

Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease

Authors
  • Lu, Ming1
  • Pontecorvo, Michael J.1
  • Devous, Michael D. Sr1
  • Arora, Anupa K.1
  • Galante, Nicholas1
  • McGeehan, Anne1
  • Devadanam, Catherine1
  • Salloway, Stephen P.2, 3
  • Doraiswamy, P. Murali4
  • Curtis, Craig5
  • Truocchio, Stephen P.1
  • Flitter, Matthew1
  • Locascio, Tricia1
  • Devine, Marybeth1
  • Zimmer, Jennifer A.6
  • Fleisher, Adam S.6
  • Mintun, Mark A.1, 6
  • 1 Avid Radiopharmaceuticals, A Wholly Owned Subsidiary of Eli Lilly and Co, Philadelphia, Pennsylvania
  • 2 Butler Hospital, Providence, Rhode Island
  • 3 Brown University, Providence, Rhode Island
  • 4 Duke University School of Medicine and the Duke Institute of Brian Science Center, Durham, North Carolina
  • 5 Independent
  • 6 Eli Lilly and Company, Indianapolis, Indiana
Type
Published Article
Journal
JAMA Neurology
Publisher
American Medical Association
Publication Date
Feb 15, 2021
Volume
78
Issue
4
Pages
445–453
Identifiers
DOI: 10.1001/jamaneurol.2020.5505
PMID: 33587110
PMCID: PMC7885097
Source
PubMed Central
Disciplines
  • Comments
License
Unknown
External links

Abstract

This study evaluates the association between flortaucipir positron emission tomography visual interpretation and patients’ near-term clinical progression of mild cognitive impairment and dementia owing to Alzheimer disease.

Report this publication

Statistics

Seen <100 times